Delivery Order SPE2DR25D2014-SPE2DR26FZ65L
- Not listed
- The Defense Logistics Agency awarded a $33,547 delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of HYPERRAB 300 units/ml, a rabies immunoglobulin product. The contract is a firm fixed-price delivery order with an ultimate completion date of December 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $3,467.48 to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. The order, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by December 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $17,908.00 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial 5ML, a rabies immunoglobulin product used in post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and represents a continuation of the company's ongoing pharmaceutical supply relationship with federal healthcare systems. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,744.80 on August 26, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immune globulin product. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 17, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $8,822.24 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Hyperrab 300 Unit/ML Vial 3ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The order will be performed at the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $10,744.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immune globulin product. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and represents a direct procurement of critical immunological...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $17,908 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product. This firm fixed-price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ65LDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,201.22 to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion by December 2, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse medical supply requirements across multiple therapeutic domains, including specialty medications, vaccines, and medical devices, consistently meeting federal procurement standards through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 11/7/25 |